Blood coagulation parameters in pregnant women with COVID-19

D. Krenytska, A. Rachkovska, O. Savchuk, V. Karbovskiy
Taras Shevchenko National University of Kyiv, Kyiv; Taras Shevchenko National University of Kyiv, Kyiv; Taras Shevchenko National University of Kyiv, Kyiv; LLC "Biopharma Plasma", Bila Tserkva


The CoViD-19 pandemic have been lasting since 2019 year. It is a serious threat for health care system around the world because a huge number of patients requires of intensive assistance. Firstly, SARS-CoV-2 causes damage of the respiratory system. However, researches demonstrate that CoViD-19 is the hidden enemy for our body. It causes suffering of other organs. Coagulopathy often develops in SARS-CoV-2 patients. It includes acute inflammation, hypercoagulation and violation of the integrity and functions of the endothelium. A lot of scientific information has accumulated about changed in the hemostatic system during deveploment of CoViD-19. However, clinical researches are ambiguous, but abnormal blood clotting is demonstrated in most hospitalized patients with acute CoViD-19. Our research is aimed to analyse the main parameters of the hemostatic system in the pregnant women with infection of SARS-CoV-2 and the comparison with conventionally healthy pregnant patients. We have revealed the concentration of fibrinogen is increasing by 2,1 g/L, levels of D-dimer are increased by 500 ng/mL, the prothrombic time is rising by 1,2 seconds in plasma of the CoViD-19 pregnant patients unlike by conventionally healthy pregnant patients. Changes in the duration of activated partial thromboplastin time weren`t detected in plasma of the CoViD-19 pregnant patients unlike by conventionally healthy pregnant patients. Our research could be useful for diagnostic complications of the hemostatic system in CoViD-19 patients, for detection of blood clotting disorders during early stages of development, suppression of the spread of pathological processes of the fetus in pregnant women and for creation of effective treatment.


SARS-CoV-2, the hemostatic system, coagulopathy, pregnant women

Full Text:



Roberts D.L., Rossman J.S., Jaric I. Dating first cases of COVID-19. PLOS Pathogens. 2021; 17(6): 1-10. doi:10.1371/journal.ppat.1009620.

Muhammad Adnan Shereen, Suliman Khan, Abeer Kazmi, Nadia Bashir, Rabeea Siddique Shereen COVID-19 infection: Emergence, transmission, and characteristics of human coronaviruses. Journal of Advanced Research. 2020; 24 (3): 91-98. doi: 10.1016/j.jare.2020.03.005.

Rabaan A.A., Al-Ahmed S.H., Haque S., Sah R., Tiwari R., Malik Y.S., Dhama K., Yatoo M.I., Bonilla-Aldana D.K., Rodriguez-Morales A.J. SARSCoV-2, SARS-CoV, and MERS-COV: A comparative overview. Infez Med. 2020, 28 (2): 174-184.

Wool G.D., Miller J.L. The Impact of COVID-19 Disease on Platelets and Coagulation. Pathobiology. 2021, 88(1): 15-27. doi: 10.1159/000512007.

Mehta P., McAuley D.F., Brown M., Sanchez E., Tattersall R.S., Manson J.J. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020, 28 (1): 1033-1034. doi: 10.1016/S0140-


Biswas I. Coagulation Disorders in COVID-19: Role of Toll-like Receptors. Journal of Inflammation Research, 2020, 13 (2): 823-828. doi:10.2147/JIR.S271768.

Veras F.P., Pontelli M.C., Silva C.M. SARS-CoV-2–triggered neutrophil extracellular traps mediate COVID-19 pathology Journal of Experimental Medicine. 2020, 217 (12): 1-12. doi:10.1084/jem.20201129.

Meini S., Zanichelli A., Sbrojavacca R. Understanding the pathophysiology of COVID-19: could the contact system be the key? Frontiers in Immunology, 2020, 11(4). doi: 10.3389/fimmu.2020.02014.

Thachil J., Cushman M., Srivastava A. A proposal for staging COVID-19 coagulopathy. Research and Practice in Thrombosis and Haemostasis, 2020, 4 (5): 731-736. doi: 10.1002/rth2.12372.

Connors J.M., Levy J.H. Thromboinflammation and the hypercoagulability of COVID-19. Journal of Thrombosis and Haemostasis, 2020, 18 (7): 1559-1561. doi: 10.1111/jth.14849.

Varga Z., Flammer A.J., Steiger P., Haberecker M., Andermatt R., Zinkernagel A.S. Endothelial cell infection and endotheliitis in COVID‐19. Lancet, 2020, 395 (1): 1417–1418. doi: 10.1016/S0140-6736(20)30937-5.

Guo T., Fan Y., Chen M., Wu X., Zhang L., He T. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID‐19). JAMA Cardiology, 2020, 5 (7): 811-8118. doi: 10.1001/jamacardio.2020.1017.

Chatterjee S., Sengupta T., Majumder S., Majumder R. COVID-19: a probable role of the anticoagulant Protein S in managing COVID-19-associated coagulopathy. Aging (Albany NY), 2020, 12 (16): 15954-15961.


Wang L., He W.B., Yu X.M., Hu D.L., Jiang H. Prolonged prothrombin time at admission predicts poor clinical outcome in COVID-19 patients. World Journal of Clinical Cases, 2020, 8 (9): 4370-4379. doi:10.12998/wjcc.v8.i19.4370.

Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. Journal of Thrombosis and Haemostasis, 2020, 4 (3): 844-847.

doi: 10.1111/jth.14768.

Huang Y., Wang X., Li L., Ren J., Zhao Y. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan. ChinaLancet, 15 (395): 497-506. doi: 10.1016/S0140-6736(20)30183-5.

Devreese K.M.J. COVID-19-related laboratory coagulation findings. International Journal of Laboratory Hematology, 2021, 1 (18): 36-42. doi: 10.1111/ijlh.13547. PMID: 34288440.

Christensen B., Favaloro E.J., Lippi G., Van Cott E.M. Hematology laboratory abnormalities in patients with coronavirus disease 2019 (COVID-19). Seminars in Thrombosis and Hemostasis, 2020, 46(7): 845-849.

Ranucci M., Ballotta A., Di Dedda U., Bayshnikova E., Dei Poli M., Resta M. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. Journal of Thrombosis and Haemostasis, 2020, 1 (1): 1747-1751.

Han H., Yang L., Liu R., Liu F., Wu K.L., Li J. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clinical Chemistry and Laboratory Medicine, 2020, 58 (7): 1116-1120. doi: 10.1515/cclm-2020-0188.

Tang N., Bai H., Chen X., Gong J., Li D., Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. Journal of Thrombosis and Haemostasis, 2020, 18 (5): 1094-1099.

Demelo-Rodríguez P., Cervilla-Muñoz E., Ordieres-Ortega L. Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D-dimer levels. Thrombosis Research, 2020, 192 (2): 23–26. doi:10.1016/j.thromres.2020.05.018.

Porfidia A., Pola R. Venous thromboembolism in COVID-19 patients. Journal of Thrombosis and Haemostasis, 2020, 18 (6): Р.1516–1517. doi:10.1111/jth.14842.

Mert İlker HayıroğluTufan, ÇınarAhmet İlker, Tekkeşin Fibrinogen and D-dimer variances and anticoagulation recommendations in CoViD-19: current literature review. Revista da Associação Médica Brasileira, -2020, 66 (6): P.45-56. doi:10.1590/1806-9282.66.6.842.

Received: 06.09.2021

Revised: 05.10.2021

Signed for publishing: 06.10.2021



  • There are currently no refbacks.

Лицензия Creative Commons
This journal is available according to the Creative Commons License «Attribution» («Атрибуція») 4.0 Global (CC-BY).